References

A peer-reviewed open-access article examining the global burden of insufficient sleep and its public health consequences. Available freely via PubMed Central using PMCID: PMC6473877.

A cross-country economic analysis covering the USA, UK, Germany, Japan, and Canada. The UK figure of up to £40 billion reflects the estimated annual GDP loss attributable to insufficient sleep, including costs from absenteeism and reduced productivity. Note: this figure reflects the broader economic cost of sleep loss and is not limited to diagnosed sleep disorders.

A clinical review providing guidance on the assessment and management of sleep problems in children. Estimates the prevalence of sleep difficulties in children aged 3–12 years at 15–30%.

An evidence-based briefing for UK parliamentarians drawing on peer-reviewed research and expert interviews. Identifies insomnia as one of the two most common sleep-wake disorders presenting to clinicians in the UK, affecting between 6–40% of the population depending on definition, and confirms it is the most prevalent sleep disorder seen in primary care.

A systematic meta-analysis of epidemiological studies examining the relationship between insomnia and cardiovascular disease risk. Found that insomnia is associated with a 45% increased risk of developing or dying from cardiovascular disease.

A meta-analysis of longitudinal epidemiological studies demonstrating that insomnia significantly increases the risk of developing depression. People with insomnia have approximately twice the risk of developing depression compared to those without sleep difficulties.

A systematic review and meta-analysis found that approximately 70% of migraine sufferers experience insomnia, demonstrating a significant bidirectional relationship between migraine and sleep disturbance.

Migraine affects approximately 1 in 3 women in the UK, making it one of the most prevalent neurological conditions disproportionately affecting women.

A 2025 study published in npj Dementia examining the relationship between sleep disturbances and subsequent neurodegenerative disease. Findings indicate that sleep disorders may impart measurable risk up to 15 years before the clinical onset of neurodegenerative conditions such as Parkinson's disease and dementia.

A cross-sectional study examining the association between chronic insomnia and a range of medical conditions. Findings showed significantly elevated odds of insomnia across all medical conditions studied, with neurological disease and any medical condition carrying the highest odds ratios (5.21 and 5.26 respectively). All results were statistically significant (p<0.05).

Large-scale survey data demonstrating that the majority of adolescents fail to achieve recommended sleep durations, with significant implications for academic performance, mental health, and metabolic health.

A comprehensive clinical review reporting that up to 75% of children and young people with neurodevelopmental, emotional, behavioural and intellectual disorders experience significant sleep problems, including insomnia and sleep maintenance difficulties, with wide-ranging impact on behaviour, cognition, and academic performance.

A landmark meta-analysis synthesising 86 studies involving 35,936 school-age children (5–12 years), demonstrating consistent associations between sleep duration, cognitive performance, and behavioural difficulties. Better sleep was significantly associated with better cognitive performance and fewer behavioural problems across multiple domains including executive function, school performance, and emotional regulation.

AASM consensus statement providing evidence-based sleep duration recommendations for children and adolescents across different age groups.

Landmark epidemiological study demonstrating the high prevalence of sleep complaints in community-dwelling older adults, with approximately half reporting difficulties with sleep onset, maintenance, or early waking.

Open-access systematic review and meta-analysis demonstrating that both benzodiazepines (RR 1.52) and Z-drugs (RR 1.90) significantly increase hip fracture risk in older adults. Critically, short-term use carried the greatest risk, with Z-drugs associated with a 2.39-fold increased risk of hip fracture even in new users — directly challenging the assumption that short-term prescribing is safe in this population.

Systematic review and meta-analysis of 55 studies involving 22,780 participants. The pooled prevalence of clinically significant sleep disturbance in people with dementia living in care homes was 20% (1 in 5), based on validated questionnaire measures. The authors note that actigraphy-based thresholds should be interpreted with caution in older populations given normal age-related changes in sleep architecture.

A clinical review of benzodiazepine use among elderly patients reporting that 25% of hypnotic users aged 65 and over had been prescribed them for more than 10 years, despite guidance recommending a maximum of 4 weeks. The paper highlights the particular risks of long-term benzodiazepine use in older adults including falls, cognitive impairment, and dependence.